SOURCE: Healtheuniverse Inc.

March 20, 2006 09:30 ET

Healtheuniverse Announces Appointment of Dr. Joseph Camarata, M.D. to Its Medical and Scientific Advisory Board

Dr. Camarata, Plastic and Reconstructive Surgeon, Joins Development Initiative to Be First to Commercialize Adult Stem Cell Therapies in Plastic, Reconstructive, and Cosmetic Surgery

COVINA, CA -- (MARKET WIRE) -- March 20, 2006 -- Healtheuniverse Inc. (OTC: HLUN), a diversified biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products, announced today that Dr. Joseph Camarata, M.D. has accepted an appointment to its Medical and Scientific Advisory Board. Dr. Camarata is a plastic and reconstructive surgeon certified by the American Board of Oral and Maxillofacial Surgery.

Dr. Camarata is currently a practicing plastic and reconstructive surgeon in Lincoln, Nebraska. Dr. Camarata received his Doctor of Medicine (M.D.) from the University of Nebraska and his Doctor of Medical Dentistry (D.M.D.) from the University of Pittsburgh, graduating from the programs with Distinction and Honors, respectively. He completed his plastic and reconstructive surgery residency program through the University of Texas Health Science Center and completed his oral and maxillofacial surgery residency through the University of Nebraska Medical Center. Dr. Camarata held the position of Chief Resident in both programs.

"We are extremely fortunate to have a surgeon of this caliber helping to guide Healtheuniverse's efforts in developing our adult stem cell applications," stated Dr. Vipul Dev, M.D., Chief Executive Officer of Healtheuniverse. "Dr. Camarata has been highly influential in the field of plastic and reconstructive surgery and his experience will be of tremendous value in all aspects of Healtheuniverse's research and clinical programs."


HEALTHeUNIVERSE Inc. is a biotechnology development firm specializing in the development and commercialization of patented Biopharmaceutical and Biomedical products. We are engaged in research and development of regenerative medicine therapies using non-embryonic adult stem cells for use in plastic, reconstructive, orthopedic, vascular, and cardiac surgery. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in the most profitable commercial applications. More information on Healtheuniverse is available online at

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Healtheuniverse Inc., and members of their management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-statements include fluctuation of operating results, the ability to compete successfully and the ability to complete before-mentioned transactions. The company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact Information

  • For more information, please contact:
    Healtheuniverse, Inc.
    Investor Relations
    Email Contact